Skip to main content
Clinical Trials/NCT05881226
NCT05881226
Recruiting
N/A

Application of Biomarkers in Neurological Diseases

Yi Yang1 site in 1 country3,000 target enrollmentJune 5, 2023
ConditionsBiomarkers

Overview

Phase
N/A
Intervention
Not specified
Conditions
Biomarkers
Sponsor
Yi Yang
Enrollment
3000
Locations
1
Primary Endpoint
mRS score in 90 days
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.

Detailed Description

With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

Registry
clinicaltrials.gov
Start Date
June 5, 2023
End Date
December 1, 2031
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Yi Yang
Responsible Party
Sponsor Investigator
Principal Investigator

Yi Yang

Associated Dean of First Hospital of Jilin University

The First Hospital of Jilin University

Eligibility Criteria

Inclusion Criteria

  • Patients with neurological diseases;
  • Subjects or legal agents agree to participate in the study and sign the informed consent.

Exclusion Criteria

  • Participating in other clinical investigators;
  • Unwilling to be followed up or poor treatment compliance;
  • Other conditions considered unsuitable for inclusion by the researchers.

Outcomes

Primary Outcomes

mRS score in 90 days

Time Frame: 3 months

The proportion of 3-month good functional outcome (mRS Score 0-2) in patients with neurological diseases was evaluated by mRS Score

Study Sites (1)

Loading locations...

Similar Trials